{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:44:48Z","timestamp":1761597888599,"version":"3.41.2"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T00:00:00Z","timestamp":1513900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Chang Gung Memorial Hospital Medical Research Program","award":["CMRPG392181","CMRPG3E0241","CORPG3G0991"],"award-info":[{"award-number":["CMRPG392181","CMRPG3E0241","CORPG3G0991"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Besides antiviral activities against hepatitis B virus (HBV), telbivudine has an extrahepatic pharmaceutical effect: to improve renal function assessed by estimated glomerular filtration rate (eGFR). However, the durability of this effect after withdrawal of telbivudine or switching to other antivirals has never been investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a postmarketing, real-world observation study for telbivudine treatment. The durability of telbivudine-associated renal function improvement was examined following withdrawal\/switching of antivirals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 160 telbivudine-treated, chronic hepatitis B patients, 21, 6, and 2 patients were loss to follow-up, dead, and pregnant during the study, respectively. Of the remaining 131 patients, 26, 47, 28, and 30 patients experienced telbivudine withdrawal, continuous use of telbivudine, switching to entecavir, or switching to tenofovir, respectively. During the first 2 years, eGFR in telbivudine-treated patients significantly improved before withdrawal\/switching of antivirals (P = .009). Thereafter, eGFR remained unchanged for &amp;gt;1 year in the withdrawal (P = .100) and continuous use (P = .517) subgroups, but decreased significantly in the switching to entecavir (P = .002) and switching to tenofovir (P &amp;lt; .001) subgroups. Multivariate logistic regression analysis revealed that switching to tenofovir and poor liver functional reserve were predictors for eGFR deterioration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Telbivudine-associated renal function improvement was durable after withdrawal or continuous use of telbivudine. However, renal function deteriorated if patients were switched to entecavir or tenofovir.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofx271","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T02:25:11Z","timestamp":1513909511000},"source":"Crossref","is-referenced-by-count":3,"title":["Durability of Telbivudine-Associated Improvement of Renal Function Following Withdrawal or Switching of Antivirals in Chronic Hepatitis B Patients"],"prefix":"10.1093","volume":"5","author":[{"given":"Chao-Wei","family":"Hsu","sequence":"first","affiliation":[{"name":"Liver Research Center, Chang Gung Memorial Hospital-Lin Kou, Chang Gung University College of Medicine, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Cheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Liver Research Center, Chang Gung Memorial Hospital-Lin Kou, Chang Gung University College of Medicine, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Ling","family":"Chang","sequence":"additional","affiliation":[{"name":"Liver Research Center, Chang Gung Memorial Hospital-Lin Kou, Chang Gung University College of Medicine, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Chun","family":"Lin","sequence":"additional","affiliation":[{"name":"Liver Research Center, Chang Gung Memorial Hospital-Lin Kou, Chang Gung University College of Medicine, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Ming","family":"Lin","sequence":"additional","affiliation":[{"name":"Liver Research Center, Chang Gung Memorial Hospital-Lin Kou, Chang Gung University College of Medicine, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"Liver Research Center, Chang Gung Memorial Hospital-Lin Kou, Chang Gung University College of Medicine, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-De","family":"Chu","sequence":"additional","affiliation":[{"name":"Liver Research Center, Chang Gung Memorial Hospital-Lin Kou, Chang Gung University College of Medicine, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chau-Ting","family":"Yeh","sequence":"additional","affiliation":[{"name":"Liver Research Center, Chang Gung Memorial Hospital-Lin Kou, Chang Gung University College of Medicine, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,12,22]]},"reference":[{"key":"2020081004170209700_CIT0001","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"volume-title":"Global Hepatitis Report 2017","year":"2017","author":"WHO","key":"2020081004170209700_CIT0002"},{"key":"2020081004170209700_CIT0003","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"2020081004170209700_CIT0004","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/infdis\/146.2.198","article-title":"Incidence of hepatitis B virus infections in preschool children in Taiwan","volume":"146","author":"Beasley","year":"1982","journal-title":"J Infect Dis"},{"key":"2020081004170209700_CIT0005","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(89)92876-6","article-title":"Horizontal transmission of hepatitis B virus","volume":"1","author":"Davis","year":"1989","journal-title":"Lancet"},{"key":"2020081004170209700_CIT0006","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1056\/NEJM197504102921503","article-title":"Vertical transmission of hepatitis B antigen in Taiwan","volume":"292","author":"Stevens","year":"1975","journal-title":"N Engl J Med"},{"key":"2020081004170209700_CIT0007","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S0140-6736(84)91694-5","article-title":"Hepatitis B virus carrier state in black children in Ovamboland: role of perinatal and horizontal infection","volume":"1","author":"Botha","year":"1984","journal-title":"Lancet"},{"key":"2020081004170209700_CIT0008","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/jmv.10332","article-title":"Secular trend of age-specific prevalence of hepatitis B surface and e antigenemia in pregnant women in Taiwan","volume":"69","author":"Lin","year":"2003","journal-title":"J Med Virol"},{"key":"2020081004170209700_CIT0009","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"key":"2020081004170209700_CIT0010","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e antigen and the risk of hepatocellular carcinoma","volume":"347","author":"Yang","year":"2002","journal-title":"N Engl J Med"},{"key":"2020081004170209700_CIT0011","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"2020081004170209700_CIT0012","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"2020081004170209700_CIT0013","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2893.2005.00608.x","article-title":"Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis","volume":"12","author":"Tseng","year":"2005","journal-title":"J Viral Hepat"},{"key":"2020081004170209700_CIT0014","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"2020081004170209700_CIT0015","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"2020081004170209700_CIT0016","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association for the Study of the Liver","year":"2012","journal-title":"J Hepatol"},{"key":"2020081004170209700_CIT0017","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.cgh.2007.05.004","article-title":"Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B","volume":"5","author":"Keeffe","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020081004170209700_CIT0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2008.12.019","article-title":"Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B","volume":"51","author":"Zeuzem","year":"2009","journal-title":"J Hepatol"},{"key":"2020081004170209700_CIT0019","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199008023230503","article-title":"A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group","volume":"323","author":"Perrillo","year":"1990","journal-title":"N Engl J Med"},{"key":"2020081004170209700_CIT0020","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-119-4-199308150-00011","article-title":"Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis","volume":"119","author":"Wong","year":"1993","journal-title":"Ann Intern Med"},{"key":"2020081004170209700_CIT0021","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"2020081004170209700_CIT0022","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"2020081004170209700_CIT0023","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group","volume":"339","author":"Lai","year":"1998","journal-title":"N Engl J Med"},{"key":"2020081004170209700_CIT0024","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/gast.2000.8559","article-title":"Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group","volume":"119","author":"Liaw","year":"2000","journal-title":"Gastroenterology"},{"key":"2020081004170209700_CIT0025","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","article-title":"Long-term safety of lamivudine treatment in patients with chronic hepatitis B","volume":"125","author":"Lok","year":"2003","journal-title":"Gastroenterology"},{"key":"2020081004170209700_CIT0026","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/jhep.2001.25084","article-title":"Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy","volume":"33","author":"Leung","year":"2001","journal-title":"Hepatology"},{"key":"2020081004170209700_CIT0027","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"2020081004170209700_CIT0028","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"2020081004170209700_CIT0029","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"2020081004170209700_CIT0030","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"2020081004170209700_CIT0031","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"2020081004170209700_CIT0032","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-230X-12-178","article-title":"Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at week 24","volume":"12","author":"Hsu","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"2020081004170209700_CIT0033","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2013.09.031","article-title":"Telbivudine improves renal function in patients with chronic hepatitis B","volume":"146","author":"Gane","year":"2014","journal-title":"Gastroenterology"},{"key":"2020081004170209700_CIT0034","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12876-017-0582-0","article-title":"Comparison of telbivudine and entecavir on the change of off- treatment eGFR after 3 years of treatment in non-cirrhotic chronic hepatitis B patients","volume":"17","author":"Lin","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"2020081004170209700_CIT0035","doi-asserted-by":"crossref","first-page":"e15074","DOI":"10.5812\/hepatmon.15074","article-title":"Decrease of serum Angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glumerular filtration rates","volume":"14","author":"Liang","year":"2014","journal-title":"Hepat Mon"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/5\/1\/ofx271\/33577357\/ofx271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/5\/1\/ofx271\/33577357\/ofx271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T08:22:05Z","timestamp":1597047725000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofx271\/4770295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,22]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofx271","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2017,12,22]]},"article-number":"ofx271"}}